Immatics' IMA402 shows 32% confirmed response rate in high-PRAME melanoma patients in Phase 1b trial
IMTX•Immatics said IMA402 showed a 32% confirmed response rate in high-PRAME melanoma patients in a Phase 1b trial. The company also reported updated early-stage results for IMA402 and IMA203CD8 across advanced solid cancers.
1. Updated trial results
Immatics reported durable responses and favorable tolerability with IMA402 in advanced melanoma; it plans to present results at the 2026 ESMO meeting. IMA203CD8 results presented at ESMO showed durable responses across several cancers, including gynecologic tumors, with manageable safety.
2. Development plans
Immatics plans to study IMA402 in combination treatments, with initial lung cancer combination data expected in 2027. A pediatric cancer trial of IMA203CD8 is planned for the first half of 2027.
